Skip to main content
Premium Trial:

Request an Annual Quote

CAT Gains Access to Incyte s Database, Secures Rights to Develop Products

NEW YORK, Dec. 19 – Cambridge Antibody Technology of Melbourn, UK, has licensed access to Incyte’s LifeSeq Gold database and obtained options for the rights to develop products based on the data, the companies said Wednesday.

CAT will use the data as well as cDNA clones Incyte provides to develop antibody therapeutic products. CAT also has the right to gain the exclusive licences from Incyte develop treatments aimed at protein targets in Incyte’s database.

In exchange, CAT will pay a licence fee, plus milestones and royalties to Incyte. 

“CAT has already demonstrated the power of combining antibody phage display and genomics-based target discovery, and this agreement adds a significant new source of genomics-derived targets to fuel CAT's drug development pipeline," David Chiswell, CEO of CAT, said in a statement. 

CAT has developed technologies for to use human monoclonal antibodies for drug discovery and drug development. The company is currently running clinical trials for six of its therapeutic antibodies.

The company employs approximately 250 people.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.